Background: researchers and sponsors increasingly confront the issue of whether
participants in a clinical trial should have post-trial access (PTA) to the trial drug. Legislation …

There are millions of individuals living in North America and the European Union who lack
access to healthcare services. When these individuals participate in research, they are at …

Objective: Research on psychopharmacological treatment in children and adolescents is the
subject of ongoing ethical discussion, as minors with mental disorders constitute a …

A common reason for giving research participants post‐trial access (PTA) to the trial
intervention appeals to reciprocity, the principle, stated most generally, that if one person …

Background Injection drug use continues to significantly contribute to new infections with
HIV. Moreover, conducting HIV prevention research with people who inject drugs (PWIDs) …

Ethics guidance increasingly recognises that researchers and sponsors have obligations to
consider provisions for post-trial access (PTA) to interventions that are found to be beneficial …

The principle of providing post‐trial access for research participants to successful products
of that research is widely accepted and has been enshrined in various declarations and …

This paper discusses so-called post-trial access to drugs for patients who participated in
clinical trials in Brazil. Brazil is currently a relevant country for the pharmaceutical industry …

Purpose Participants' rights and safety must be guaranteed not only while a clinical trial is
being conducted but also when a clinical trial finishes. The criteria for post-trial access to …

A continuidade do tratamento com os medicamentos investigacionais após a conclusão de
uma pesquisa clínica vem sendo discutida desde o final dos anos 1980, inicialmente em …